|
Test ID: Marginal Malt Lymphoma Panel By FISH
|
|
Marginal Malt Lymphoma Panel By FISH
|
|
Marginal Malt Lymphoma is detected by FISH procedure.
|
|
Method name and description
|
Interphase Fluorescence In Situ Hybridization (I-FISH) study.
|
|
Clinical information
|
Marginal Zone Lymphoma (MZL) includes two lymphoid neoplasms: an extranodal marginal zone lymphoma of Mucosa-Associated Lymphoid Tissue (MALT lymphoma) and nodal MZL; the previous is more common than the last mentioned and affects the GI tract, while MZL affects peripheral lymph nodes predominately.
FISH test is outlined by specific target probes that detect the most significant abnormalities in MZL. (Swerdlow et al. 2008). FISH studies complement the chromosome analysis, particularly when analyzing the abnormal clone pertaining to relapse and progression, or when the specimen quantity is insufficient for chromosomal analysis.
|
|
|
Specimen type / Specimen volume / Specimen container
|
1. Specimen Type: Blood/Leukemic Blood
Container/Tube: Green top (sodium heparin)
Specimen Volume: 2-6 mL (Varies depending on the WBC-Count).
(Adult - 3-6 mL ,Child - 2 mL, Infant - 2 mL)
2. Specimen Type: Bone marrow
Container/Tube: Bone Marrow Transport Media
Specimen Volume: 1-3 mL (Varies depending on the WBC-Count).
|
|
Collection instructions / Special Precautions / Timing of collection
|
Sunday-Wednesday 7:00- 14:00
|
|
Storage and transport instructions
|
|
|
|
Specimen Rejection Criteria
|
Consistent with Diagnostic Genomic Division policies.
|
|
|
Factors affecting test performance and result interpretation
|
MALT lymphoma an extra-nodal introduction of Marginal Zone B-Cell Lymphomas (MZBCL). The foremost common anomalies in extra-nodal MZBCL of MALT type contains: target t(11;18)(q21;q21) / API2-MLT fusion, this translocation is associated with low-grade MALT lymphoma of the stomach, and of the lung. Critically, this translocation was associated with rise of determined disease or recurrence after HP eradication therapy.
The translocation t(14;18)(q32;q21)/IgH-MLT1 fusion, enhances MLT1 expression in all MALT lymphomas. It pertains to the MALT lymphoma of the skin, lung, liver, visual adnexa, and salivary gland, but not observed in MALT lymphomas of the stomach, digestive system, thyroid, or breast.
|
|
Turnaround time / Days and times test performed / Specimen retention time
|
|
|
|
|
